title: The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B.
abstract: Human APOBEC3B (A3B) has been described as a potent inhibitor of retroviral infection and retrotransposition. However, we found that the predominantly nuclear A3B only weakly restricted infection by HIV-1, HIV-1Δvif, and human T-cell leukemia virus type 1 (HTLV-1), while significantly inhibiting LINE-1 retrotransposition. The chimeric construct A3G/B, in which the first 60 amino acids of A3B were replaced with those of A3G, restricted HIV-1, HIV-1Δvif, and HTLV-1 infection, as well as LINE-1 retrotransposition. In contrast to the exclusively cytoplasmic A3G, which is inactive against LINE-1 retrotransposition, the A3G/B protein, while localized mainly to the cytoplasm, was also present in the nucleus. Further mutational analysis revealed that residues 18, 19, 22, and 24 in A3B were the major determinants for nuclear versus cytoplasmic localization and antiretroviral activity. HIV-1Δvif packages A3G, A3B, and A3G/B into particles with close-to-equal efficiencies. Mutation E68Q or E255Q in the active centers of A3G/B resulted in loss of the inhibitory activity against HIV-1Δvif, while not affecting activity against LINE-1 retrotransposition. The low inhibition of HIV-1Δvif by A3B correlated with a low rate of G-to-A hypermutation. In contrast, viruses that had been exposed to A3G/B showed a high number of G-to-A transitions. The mutation pattern was similar to that previously reported for A3B, with a preference for the GA context. In summary, these observations suggest that changing 4 residues in the amino terminus of A3B not only retargets the protein from the nucleus to the cytoplasm but also enhances its ability to restrict HIV while retaining inhibition of retrotransposition.
authors.affiliation: HIV Drug Resistance Program, National Cancer Institute, P.O. Box B, Frederick, MD 21702-1201, USA.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Pak
authors.forename: Gisela
authors.initials: G
authors.lastname: Heidecker
authors.forename: Vinay K
authors.initials: VK
authors.lastname: Pathak
authors.forename: David
authors.initials: D
authors.lastname: Derse
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D000998:Antiviral Agents / Q000276:immunology* / Q000378:metabolism; D002460:Cell Line; D002467:Cell Nucleus / Q000737:chemistry; D003564:Cytidine Deaminase / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D003593:Cytoplasm / Q000737:chemistry; D015497:HIV-1 / Q000254:growth & development / Q000276:immunology*; D015368:Human T-lymphotropic virus 1 / Q000254:growth & development / Q000276:immunology*; D006801:Humans; D015778:Minor Histocompatibility Antigens; D050505:Mutant Proteins / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D015778:Minor Histocompatibility Antigens; D050505:Mutant Proteins; C495794:APOBEC3B protein, human; D003564:Cytidine Deaminase